Opinion ID: 4470746
Heading Depth: 3
Heading Rank: 1

Heading: A ready to use liquid pharmaceutical composi-

Text: tion for parenteral administration to a subject, comprising dexmedetomidine or a pharmaceuti- cally acceptable salt thereof disposed within a sealed glass container, wherein the liquid pharmaceutical composition when stored in the glass container for at least five months exhibits no more than about 2% decrease in the concentration of dexmedetomidine. Id. col. 26 ll. 18–24. Claim 6, which depends from claim 1, is the only claim at issue in this appeal: 6 HOSPIRA, INC. v. FRESENIUS KABI USA, LLC 6. The ready to use liquid pharmaceutical composition of claim 1, wherein the dexmedetomidine or pharmaceutically acceptable salt thereof is at a concentration of about 4 µg/mL. Id. col. 26 ll. 41–43.